Cancer clinical trial database.
Every new trial and trial result from New in Oncology, our weekly research briefing, since the first issue on . Search by NCT number, drug, or cancer type.
All entries in chronic lymphocytic leukemia
- New trial
Chronic lymphocytic leukemia
Phase 1b/2 roginolisib PI3K-delta inhibitor with sequential obinutuzumab and venetoclax after BTK inhibitors in CLL
Dana-Farber Cancer Institute is running a Phase 1b/2, open-label, single-arm study testing roginolisib (IOA-244), a selective, allosteric PI3K-delta inhibitor developed by iOnctura, in relapsed or refractory chronic…
NCT07847957 Exploratory - Trial result Spotlight
Chronic lymphocytic leukemia
Ibrutinib (BTK inhibitor) + venetoclax (BCL-2 inhibitor) improves long-term OS/PFS in 1L CLL, with more progression-free time without grade 3/4 AEs
Fixed-duration ibrutinib-venetoclax is an all-oral BTK/BCL-2 doublet evaluated in the Phase 3 GLOW trial (NCT03462719) in older/comorbid, previously untreated CLL, randomized vs chlorambucil-obinutuzumab (n=106 vs…
NCT03462719 - Trial result
Chronic lymphocytic leukemia
Safimaltib (JNJ-67856633) MALT1 inhibitor posts 28.8% pooled ORR across heavily pretreated B-cell lymphomas and CLL, with frequent hyperbilirubinemia
Safimaltib is an oral, once-daily MALT1 (paracaspase) protease inhibitor designed to dampen B-cell receptor/NF-κB signaling and was evaluated in a multi-center Phase 1 dose-escalation/expansion study in…
NCT03900598 - New trial Spotlight
Chronic lymphocytic leukemia
Phase 3 DAYBreak CLL-306 compares bexobrutideg BTK degradation with pirtobrutinib after covalent BTK inhibition
Nurix Therapeutics’ randomized, open-label, multicenter DAYBreak CLL-306 study compares bexobrutideg (NX-5948), a small-molecule Bruton tyrosine kinase protein degrader, with pirtobrutinib, Eli Lilly’s noncovalent…
NCT07516093 Registrational - New trial
Chronic lymphocytic leukemia
Phase 2 epcoritamab CD3×CD20 consolidation seeks deeper remissions after at least 6 months of BTK inhibition in high-risk CLL
This Phase 2, single-arm, open-label UC Irvine study evaluates epcoritamab consolidation in chronic lymphocytic leukemia with residual disease while receiving a Bruton tyrosine kinase inhibitor (BTKi). Epcoritamab,…
NCT07819214 Exploratory - New trial
Chronic lymphocytic leukemia
Phase 2 zanubrutinib (BTK inhibitor) + sonrotoclax (BCL-2 inhibitor) in relapsed CLL/SLL
City of Hope Medical Center is running ZeuS-2, a Phase 2, fixed-duration, all-oral combination study evaluating zanubrutinib (a covalent Bruton tyrosine kinase inhibitor that blocks B-cell receptor signaling) with…
NCT07812246 Exploratory - New trial
Chronic lymphocytic leukemia
Phase 2 venetoclax (BCL-2 inhibitor) + zanubrutinib (BTK inhibitor) in CLL/SLL
This Phase 2 study evaluates a time-staggered oral doublet—zanubrutinib first, then venetoclax added starting cycle 4—to deepen responses and reduce measurable residual disease in chronic lymphocytic leukemia/small…
NCT07734038 Exploratory - Trial result Spotlight
Chronic lymphocytic leukemia
Pirtobrutinib (non-covalent BTK inhibitor) + venetoclax-rituximab lifts PFS vs VR in relapsed CLL/SLL
Pirtobrutinib (LOXO-305; a reversible/non-covalent BTK inhibitor) was added to fixed-duration venetoclax (BCL2 inhibitor) + rituximab (anti-CD20) in BRUIN CLL-322, an open-label, randomized Phase 3 trial in…
NCT04965493 - Trial result
Chronic lymphocytic leukemia
SAVE: Obinutuzumab + venetoclax (BCL-2 inhibitor) compresses the 5-week ramp-up to 7 inpatient days with 0 clinical TLS
In the Phase Ib SAVE study (NCT04843904), venetoclax (VEN), an oral BCL-2 inhibitor, was initiated with an accelerated *daily* inpatient ramp-up (20→400mg) in CLL, almost universally combined with the anti-CD20…
NCT04843904 - Trial result
Chronic lymphocytic leukemia
BOVen (zanubrutinib BTK inhibitor + venetoclax BCL2 inhibitor + obinutuzumab anti-CD20) delivers 92% blood+marrow uMRD4 with ~80% 4-year PFS in frontline CLL
BOVen combines zanubrutinib (covalent BTK inhibitor), venetoclax (BCL2 inhibitor), and obinutuzumab (type II anti-CD20 mAb) as an MRD-driven, time-limited triplet in a multicentre, single-arm Phase 2 frontline…
NCT03824483 - Trial result
Chronic lymphocytic leukemia
BR induction + BCL2 inhibitor venetoclax/CD20 rituximab consolidation delivers 83% BM uMRD and 87.5% 3-year PFS in frontline CLL
Short-course bendamustine/rituximab (alkylator + anti-CD20) followed by venetoclax/rituximab (BCL2 inhibitor + anti-CD20) was tested as a time-limited, single-arm Phase 2 regimen in previously untreated CLL/SLL…
NCT03609593 - Trial result Spotlight
Chronic lymphocytic leukemia
Sonrotoclax (BCL2 inhibitor) + zanubrutinib (BTK inhibitor) drives 99% PB uMRD4 and 100% 30-mo PFS in 1L CLL/SLL
Sonrotoclax (BGB-11417) is a next-generation oral BCL2 inhibitor combined with the oral BTK inhibitor zanubrutinib in the Phase 1/1b BGB-11417-101 study (NCT04277637) in treatment-naive CLL/SLL (sonro 320 mg cohort;…
NCT04277637 - Trial result
Chronic lymphocytic leukemia
Liso-cel (CD19 CAR-T) delivers 84% ORR/55% CR in heavily pretreated R/R CLL (CIBMTR)
Lisocabtagene maraleucel (liso-cel) is an autologous CD19-directed CAR T-cell therapy evaluated in a US CIBMTR real-world observational cohort of commercial use (May 2024–Sep 2025) in R/R CLL (n=45), with patients…
- Trial result
Chronic lymphocytic leukemia
Pirtobrutinib Reaches 93% ORR and 93% 24-Month PFS in Frontline CLL/SLL
Pirtobrutinib is a selective, reversible, non-covalent BTK inhibitor evaluated as continuous monotherapy in treatment-naïve CLL/SLL using pooled pirtobrutinib arms from BRUIN CLL-313 and BRUIN CLL-314 (n=253; safety…
- New trial Spotlight
Chronic lymphocytic leukemia
Phase 3 sonrotoclax (BGB-11417) BCL2 inhibitor plus zanubrutinib BTK inhibitor in untreated CLL
BeOne Medicines’ Phase 3 open-label, randomized study (BGB-11417-304; CELESTIAL‑TNCLL‑2) tests whether fixed-duration sonrotoclax + zanubrutinib can improve outcomes versus a fixed-duration control of venetoclax +…
NCT07277231 Registrational - New trial Spotlight
Chronic lymphocytic leukemia
Phase 3 rocbrutinib (LP-168) dual covalent/reversible BTK inhibitor vs pirtobrutinib non-covalent BTK inhibitor.
Newave Pharmaceutical is running this Phase 3, randomized, open-label, global multicenter trial in relapsed/refractory CLL/SLL after prior covalent BTK inhibitor therapy, enrolling ~306 adults and randomizing 1:1 to…
NCT07342478 Registrational - New trial
Chronic lymphocytic leukemia
Phase 2 AVT triplet: tafasitamab (CD19 mAb) + acalabrutinib (BTK inhibitor) + venetoclax (BCL-2 inhibitor)
This Phase 2, open-label study at City of Hope tests whether adding tafasitamab (a CD19-directed monoclonal antibody marketed as Monjuvi by Incyte and MorphoSys/Novartis) to the acalabrutinib + venetoclax backbone…
NCT07582159 Exploratory - New trial
Chronic lymphocytic leukemia
Phase 2 mosunetuzumab CD20×CD3 bispecific antibody T‑cell engager for MRD+ CLL/SLL
This MD Anderson Cancer Center, open-label, single-group Phase 2 study tests whether adding mosunetuzumab—a CD20×CD3 T‑cell–engaging bispecific antibody from Genentech/Roche—can eradicate measurable residual disease…
NCT07566364 Exploratory - New trial
Chronic lymphocytic leukemia
Phase 2 nemtabrutinib reversible non-covalent BTK inhibitor + venetoclax BCL-2 inhibitor in frontline CLL/SLL.
This Phase 2, single-arm frontline study evaluates an all-oral combination of nemtabrutinib (MK-1026)—a reversible, non-covalent Bruton’s tyrosine kinase (BTK) inhibitor that can inhibit wild-type BTK and some BTK…
NCT07557056 Exploratory - New trial
Chronic lymphocytic leukemia
Phase 2 trial: Epcoritamab, CD20/CD3 bispecific antibody
This Phase 2 study evaluates Epcoritamab, a bispecific antibody that binds CD20 and CD3, as consolidation therapy in patients with CLL/SLL or variants following 2nd-line treatment with a 2nd generation BTKi.…
NCT07108998 Exploratory - New trial
Chronic lymphocytic leukemia
Phase 1b Mosunetuzumab CD20/CD3 bispecific mAb trial in relapsed CLL/SLL patients
This pilot study evaluates mosunetuzumab administered alone or with a BTK inhibitor (ibrutinib, acalabrutinib, zanubrutinib, or pirtobrutinib, which inhibit Bruton tyrosine kinase) in participants with chronic…
NCT07052695 Exploratory - New trial
Chronic lymphocytic leukemia
Phase 2 LP-168 small molecule inhibitor and obinutuzumab CD20 mAb in CLL/SLL.
This multicenter parallel 2-cohort trial evaluates LP-168 with obinutuzumab in previously treated CLL/SLL patients, including those with a BTK gatekeeper T474 mutation. The study aims to assess safety and preliminary…
NCT06978088 Exploratory - New trial
Chronic lymphocytic leukemia
Phase 3 Study: Sonrotoclax, BCL2 Inhibitor, with Anti-CD20 Therapies in R/R CLL/SLL.
This trial compares sonrotoclax combined with anti-CD20 antibodies to standard venetoclax plus rituximab in adults with relapsed/refractory CLL/SLL receiving second-line or later therapy. Conducted at multiple…
NCT06943872 Registrational - Trial result
Chronic lymphocytic leukemia
Zanubrutinib Holds a 72% 5-Year PFS in del(17p) Front-Line CLL/SLL
Zanubrutinib, a selective next-gen BTK inhibitor, was given as continuous monotherapy to 111 treatment-naïve CLL/SLL patients with high-risk del(17p) in the non-randomized SEQUOIA arm C (NCT03336333). After a median…
NCT03336333 - New trial
Chronic lymphocytic leukemia
Phase II venetoclax (BCL2 inhibitor) plus acalabrutinib in first-line CLL/SLL
This randomized Phase II study compares intermittent (7-day) versus continuous (28-day) venetoclax dosing with acalabrutinib in previously untreated CLL/SLL patients. Conducted in Cincinnati, the trial aims to…
NCT07014917 Exploratory - New trial
Chronic lymphocytic leukemia
Phase II pirtobrutinib BTK inhibitor trial in relapsed CLL/SLL.
M.D. Anderson Cancer Center is conducting this Phase II trial evaluating a time-limited, four‐week combination of pirtobrutinib, venetoclax, and obinutuzumab in relapsed chronic lymphocytic leukemia/small lymphocytic…
NCT06967610 - New trial
Chronic lymphocytic leukemia
Phase 3 Study of BGB-16673, a BTK protein degrader, in CLL/SLL patients.
This study compares BGB-16673 monotherapy against investigator's choice regimens (idelalisib plus rituximab, bendamustine plus rituximab, or venetoclax plus rituximab retreatment) in patients with chronic lymphocytic…
NCT06846671
Looking for trials that fit a specific diagnosis? Read our guide on how to find a clinical trial, or subscribe to New in Oncology to get each issue by email.